54 results about "Hematology" patented technology

The present invention relates to a system and a method for measuring and analyzing minimal residual disease (MRD) in pediatric B-cell precursor acute lymphoblastic leukemia (B-ALL) using multiparameter flow cytometry (MPFC). The invention finds application in clinical diagnostics and hematology-oncology for quantifying MRD in B-ALL patients with high sensitivity and specificity, needed for risk stratification, monitoring treatment response, and informing therapeutic decisions. The system comprises interconnected subsystems including an acquisition subsystem with an MPFC instrument, a control and file generation subsystem, and an analytical subsystem. The analytical subsystem incorporates modules for sequential data reduction, automated data cleaning, automated unsupervised data clustering, and interactive cluster analysis. Key advantages include high MRD detection sensitivity (e.g., 10⁻⁵ or 0.001%) and high specificity, without reliance on reference samples or supervised machine learning models, making it applicable in laboratories with different measuring equipment and using different panels of antibodies for identification of leukemic cells.

The invention provides a papillary thyroid carcinoma neck lymph node metastasis risk prediction method and system based on blood indexes and TI-RADS grading, and relates to the technical field of medical data analysis. According to the method, an original data set is constructed by obtaining TI-RADS classification, the maximum diameter of nodules, the number of nodules, gender, age and conventional hematology indexes including apolipoprotein B and carcino-embryonic antigen of a patient, characteristic variables are screened by adopting LASSO regression, and an independent prediction risk factor model is established in combination with multi-factor Logistic regression. And further constructing a column graph model, carrying out performance verification through multiple statistical indexes, and deploying the model to a webpage calculator based on a shiyapp to realize convenient output of the individualized risk probability. According to the method, efficient and accurate prediction of the preoperative lymph node metastasis risk is realized, and reliable decision support can be provided for clinic.

This invention describes CD33 antibodies and their antigen-binding fragments, as well as CD33 / vδ2 multispecific antibodies or their antigen-binding fragments. The invention also describes polynucleotides encoding these antibodies, compositions comprising these antibodies, methods for producing these antibodies, and methods for treating or preventing diseases such as hematological cancers using these antibodies.

The utility model discloses a blood cell smear auxiliary device. The blood cell smear auxiliary device comprises a blood filling pool and an adjusting part, the blood filling pool is provided with a containing groove used for containing blood, the groove bottom face of the containing groove is opened to be used for being matched with a glass slide, and the adjusting part comprises a first adjusting piece and a second adjusting piece. The first adjusting piece and the second adjusting piece are oppositely arranged in the blood filling pool, and the first adjusting piece and the second adjusting piece can move so as to adjust the volume of the containing groove. According to the blood cell smear auxiliary device, the preparation efficiency and quality of the blood smear can be remarkably improved, and a more reliable sample is provided for hematological examination, so that the accuracy and efficiency of medical diagnosis are promoted.

The present disclosure discloses methods and systems for detecting cancer and / or determining tissue of origin of cancer. In some embodiments, a multi-classification cancer classifier is disclosed that is trained using a plurality of biological samples containing cfDNA fragments. The analysis system derives a feature vector for each sample, and the multi-classification classifier predicts a probabilistic likelihood for each of a plurality of cancer signal origin (CSO) classifications. In some embodiments, the plurality of CSO classifications include hematological subtypes, including both hematological malignancies and precursor conditions. In one embodiment, non-cancer samples with high predictive scores are rejected from a training sample set. In another embodiment, the analysis system stratifies the sample according to a predicted score and applies a binary threshold cutoff value determined for each stratification.

The application relates to the technical field of blood cell separation machines, in particular to a blood cell separation machine device for hematology nursing, which comprises a stirring mechanism, a feeding mechanism, a drawing mechanism, a centrifugal mechanism and a separation mechanism. The upper end of the stirring mechanism is provided with the feeding mechanism, the lower end of the feeding mechanism is provided with the drawing mechanism, the lower end of the drawing mechanism is provided with the centrifugal mechanism, and the centrifugal mechanism is provided with the separation mechanism at one end. The rotating stirring blade can uniformly mix blood and anticoagulant, preventing the blood from coagulating before centrifugation. The second sliding block and the first connecting pipe are in sliding cooperation, so that the anticoagulant can be automatically and quantitatively added into the cylinder. The second sleeve can draw the blood in the cylinder to the test tube when the first motor stops rotating. The sliding pipe and the second fixed block can quickly take out the separated blood plasma. The third sliding block can be pulled outward to take out the remaining blood cells conveniently and quickly.

A slide imaging device (110) for digital morphology in hematology is disclosed, comprising at least one z-axis stage (112) configured to place a microscope slide (114) at a sample plane, wherein a biological sample may be placed on the microscope slide (114), wherein the z-axis stage (112) is configured to set a relative distance along the optical axis (118) of the slide imaging device (110) between the microscope slide (114) and the imaging system (116) of the slide imaging device (110). The slide imaging apparatus (110) further includes at least one sample beam path and at least one autofocus beam path, the at least one autofocus beam path including at least one pattern illumination source (132), the at least one pattern illumination source including at least one light emitter (134) and at least one grating (136), wherein the grating (136) is tilted relative to the optical axis (118) of the slide imaging apparatus (110), wherein the autofocus beam path includes at least one second transmission system (140) and at least one autofocus camera (138), wherein the second transmission system (140) is configured to allow a pattern generated by the pattern illumination source (132) to be projected onto the sample plane and to allow a pattern reflected from the sample plane to be propagated to the autofocus camera (138), wherein the autofocus camera (138) is configured to generate at least one digital autofocus image of the pattern reflected from the sample plane. The slide imaging apparatus (110) further includes at least one processing unit (148) configured to analyze the digitally autofocused image, wherein the analysis includes spatial analysis of contrast and determination of the image location with maximum contrast. The slide imaging apparatus (110) further includes at least one control unit (150) configured to control the z-axis stage (112) taking into account the determined image location to position the microscope slide (114) along the optical axis (118) of the slide imaging apparatus (110).

The invention discloses a specialized nurse-oriented blood purification personalized course recommendation method and system, and relates to the technical field of medical teaching. The method comprises the following steps: S1, collecting blood purification operation data, and preprocessing the blood purification operation data; s2, dividing the preprocessed blood purification operation data into four stages, and calculating corresponding operation characteristic values; S3, obtaining operation capability characterization parameters of each stage, constructing a nurse operation evaluation model, and outputting a blood purification operation evaluation value of a nurse; and S4, generating a personalized learning task package based on the hematopurification operation evaluation value and the weight coefficient of each stage, pushing the personalized learning task package to a nurse side, constructing an evaluation difference matrix before and after learning, and performing closed-loop updating of course recommendation. The problem that an existing nurse training system cannot achieve objective evaluation and precise course matching based on multi-dimensional data of the hematology operation process, and consequently learning content is general and insufficient in individuation is solved.

The invention provides a tool for intelligently evaluating the dystrophy risk of a patient with nasopharyngeal carcinoma, and the tool for evaluating the specific dystrophy of nasopharyngeal carcinoma is constructed by integrating indexes such as social demographic data, physique measurement, tumor staging, chemoradiotherapy conditions, recent adverse reactions and hematology indexes, so that high-precision risk evaluation is realized. Through single-factor and multi-factor analysis, the variable weight is optimized, and the discrimination capability and stability of the model are improved. An intelligent applet based on artificial intelligence is developed, patient data are extracted, nutrition risk calculation is completed within seconds, evaluation time is shortened, and clinical working efficiency is improved. The system also has the functions of dynamic monitoring and intelligent early warning, automatically updates the evaluation result along with the treatment progress of the patient, and provides individualized intervention suggestions. The defects that a traditional nutrition evaluation tool is high in subjectivity, low in efficiency, lack of tumor specificity and low in informatization degree are overcome, and an efficient, accurate and automatic intelligent evaluation solution is provided for clinic.

The invention relates to a device, method and arrangement for treating the waste fluid (1) of a haematological analysis device (2), in particular for reducing or removing contaminants from the waste fluid (1) of a blood count apparatus, comprising: – an inlet (3) for introducing the waste fluid (1), – a filter device (5) disposed downstream of the inlet (3) in the flow direction (4) of the waste fluid (1) and serving to filter the waste fluid (1), – a sterilisation device (6) disposed downstream of the inlet (3) and in particular downstream of the filter device (5) in the flow direction (4) of the waste fluid (1) and serving to at least partially sterilise the waste fluid (1), – an outlet (7) for discharging the treated waste fluid (1).

This invention discloses 6-substituted 2-([1,1'-biphenyl]-4-yl)quinoline-4-carboxylic acid analogs, which are inhibitors of dihydroorotate dehydrogenase (DHODH) with improved pharmacokinetic properties. The disclosed compounds can be used to treat a variety of disorders and diseases where inhibition of DHODH may be clinically useful, including cancers such as hematologic cancers, including acute myeloid leukemia (AML), graft-versus-host disease, autoimmune disorders, and disorders associated with T-cell proliferation. When administered orally, the disclosed compounds exhibit flipped kinetics, i.e., pharmacokinetics in which the absorption rate, rather than the elimination rate, dominates the pharmacokinetic profile. The disclosed compounds exhibit sustained pharmacokinetic characteristics rather than immediate release characteristics. This summary is intended as a scanning tool for searching in a specific field and is not intended to limit this disclosure.

The present invention relates to the adoptive therapy using notably CAR-T cells. Here the inventors used a lentiviral vector approach to silence RINF expression in a shRNA-dependent manner and evaluate the consequences of RINF silencing on human CAR-T cells proliferation ex vivo and their functionality and capacity to eradicate tumor cells in vivo. More, the proposed methodology to improve CAR-T cells persistence and efficacy by disrupting RINF / CXXC5 is not restricted to patients suffering from hematological or solid cancers (anti-CD19, anti-EGFR, anti-BCMA . . . ) but could be also used to improve the efficacy of ACT in non-cancer diseases by such as lupus (1), cardiac fibrosis (2) or aging related-disorders (3). Thus, the present invention relates to an immune cell characterized in that it is defective for RINF.

1. The name of the design product: blood coagulation instrument. 2. The use of the design product: for blood test in department of hematology. 3. The design points of the design product: in shape. 4. The picture or photo that can best show the design points: perspective view.

The invention relates to a method and a kit for generating nucleic acid for target capture. The method involves binding of a circ-olio sequence to at least one target oligonucleotide to generate a single stranded circular DNA. The single stranded circular DNA is bidirectionally amplified with the sense and antisense oligonucleotides, followed by biotinylation to obtain for a double-stranded concatemer of linear sequence. The double-stranded concatemer of linear sequence with the restriction endonucleases produces a target capture nucleic acid. The method offers a scalable targeted capture of pr eselected genomic regions, and is cost effective. The method of generating nucleic acid for target capture has application in the field of oncology hematology, inherited malignancies, germline disorders, microbiology and prenatal diagnosis. The invention generates baits over high GC-rich regions of the genome.

The disclosure features calibration fluids that include a plurality of beads, such as cellulose, silica, poly(methyl-methacrylate) (PMMA), melamine, cross-linked agarose, polyvinylacetate (PVA), and / or polystyrene beads, where the beads are sized and colored to represent at least one type of blood cell; and a carrier fluid, that can include a polymer or polymerizing matrix, e.g., a water-soluble resin, e.g., an acrylic or polyurethane water-soluble resin or a starch or a cellulose, serum, and / or one or more or sugars. The disclosure also features methods of using the calibration fluids to calibrate automated sample preparation systems, such as automated hematology analyzer systems, e.g., image-based hematology analyzer systems.

The application discloses a kind of targeted dual anti-apoptotic protein polymer micelles and its preparation method and application, to overcome single drug resistance with two kinds of small molecule drugs for inhibiting the expression of anti-apoptotic protein BCL-2 and MCL-1 simultaneously loaded by polymer carrier.VEN and SOR in clinical treatment are obviously hematological toxicity due to the need to use high dose, reduce the overall treatment effect, the application discloses new targeted dual anti-apoptotic protein polymer micelles, effectively solve the problems of large dose, toxicity in the prior art.The experimental results show that TPMs-V / S effectively reduces the dose, toxic side effects of VEN and SOR, effectively improves the curative effect of double drug.

This invention relates to the field of hematology analysis technology, and in particular to a diluent for hematology analysis, its preparation method, and its uses. The diluent comprises the following components: 0.5-15 g / L of inorganic salt, 0.01-5.0 g / L of preservative, and 0.1-0.5 g / L of stabilizing agent; the solvent of the diluent is water; the diluent also includes an anti-precipitant, selected from one or more of salt-based and organic anti-precipitants; the salt-based anti-precipitant includes one or more of thiocyanate and nitrate, with a content of 2.0-5.0 mmol / L; the organic anti-precipitant includes one or more of trehalose, mannitol, and amino acid ionic liquids, with a content of 4.0-8.0 mmol / L. In this diluent, the components work synergistically to reduce the maintenance cost of the hematology analyzer, increase its service life, and improve detection efficiency.

The invention provides a preparation method of an experimental animal bone marrow smear, and belongs to the technical field of hematological examination. According to the invention, a specific smear method is matched with homologous serum, so that the mechanical damage of bone marrow cells in the collection and smear preparation process can be obviously reduced, and the phenomena of excessive crushing and uneven distribution of the cells are effectively avoided, so that the high-quality bone marrow smear with complete cell morphology and clear background is prepared; therefore, the morphological observation effect and the reading success rate of the bone marrow cells are directly improved, reliable technical guarantee is provided for accurately evaluating the influence of the test substance on the hematopoietic function of the animal in non-clinical toxicity research, and the accuracy and repeatability of experimental results are enhanced.

The bone marrow puncture extraction device comprises an extraction assembly, the bottom end of the extraction assembly is connected with a limiting sleeve, rectangular grooves are symmetrically formed in the two sides of the limiting sleeve, positioning plates are arranged in the rectangular grooves of the limiting sleeve, the positioning plates are in sliding connection with a finger plate, and the finger plate is connected with the limiting sleeve; and the bottom end of the fingerboard is provided with a groove which is connected with the supporting rod in a clamping manner. According to the bone marrow puncture extraction device for the leukemia patient in the hematology department, the butt joint pipe at one end of the extraction pipe is directly in threaded connection with the connecting pipe to form a bone marrow puncture extraction structure, and the limiting ring arranged in the butt joint pipe is in linkage with the anti-overflow block to form a corresponding non-return structure; the limiting ring and the spill-proof block are separated and opened, the puncture needle is inserted into the body of a patient, marrow fluid penetrates through the limiting ring and the spill-proof block and flows into the extraction tube, and after extraction is completed, the limiting ring and the spill-proof block are closed to form a sampling tube.

This invention discloses a comfortable lumbar spine care device for hematological rehabilitation, belonging to the technical field of lumbar spine care devices. It includes a lumbar pillow and a massage component. A pair of straps are fixedly connected to both sides of the lumbar pillow. A set of symmetrical elastic pockets is fixedly connected to the front of the lumbar pillow, and a heater is fixedly connected to the front of the lumbar pillow, located on the opposite side of the elastic pockets. A base plate is fixedly connected inside the lumbar pillow, and a pair of movable frames are movably connected inside the base plate. This invention, through a designed moving mechanism, gradually reduces the angle between connecting rod one and connecting rod two, thereby achieving a protruding effect. At this time, the insertion rod moves away from the insertion hole, and the return spring extends within the insertion hole. Thus, by controlling the angle between connecting rod one and connecting rod two, the distance between the lumbar pillow and the chair is controlled, thereby providing more stable support for the lumbar pillow, improving its stability, and ensuring stable operation during use.

This invention discloses a hematology chemotherapy drug propulsion device, relating to the field of medical injection devices. It solves the problems of precise injection speed control and inadequate disposal of used needles and syringes in existing hematology chemotherapy drug propulsion devices. The device includes a housing, a propulsion mechanism, and a destruction mechanism. The housing has an internal cavity. The propulsion mechanism includes a sliding frame, a first locking frame, and a second locking frame. The destruction mechanism includes a top cover and a crushing blade. This invention allows for precise aspiration and injection of the drug by controlling the positions of the first and second locking frames through the propulsion mechanism, thereby positioning and driving the syringe and piston rod separately. The top cover covers the upper part of the cavity, encasing the syringe. After injection, the destruction mechanism controls the needle to slide into the cavity, and the two sets of crushing blades rapidly impact the outer walls of the needle and syringe, preventing the needle and syringe from being reused.

The application provides a blood injection device, which comprises an injection cylinder and a push rod, the push rod is connected with a first piston and extends into the inner cavity of the injection cylinder, the front end of the injection cylinder is provided with a connecting end, the connecting end is provided with a through hole which is connected with the inner cavity, the inner wall of the through hole is provided with a ring of bosses, the cylindrical part of the circular part can extend into the inner ring of the bosses, the outer diameter of the connecting head is equal to the inner diameter of the through hole, the inner diameter of the connecting head is equal to the outer diameter of the cylindrical part, the cylindrical part corresponds to an injection connecting pipe, the outer diameter of the cylindrical part is equal to the outer diameter of the injection connecting pipe, the first piston is provided with a clamping groove which can be in interference fit with the circular part; when the connecting head extends into the through hole and abuts against the bosses, the injection connecting pipe pushes the cylindrical part to move so that the circular part is clamped into the clamping groove. According to the application, the connecting head extends into the through hole, the end of the injection connecting pipe in the connecting head pushes the cylindrical part to move during the extension process, and then the cylindrical part is clamped into the clamping groove, the whole process avoids the direct contact between the inner cavity and air, and can reduce the risk of infection.

The application provides a blood department ward ventilation system, which comprises a left base plate and a right base plate, the left base plate is connected to the right base plate through an arc-shaped connecting plate, a wind wheel is installed in the arc-shaped connecting plate, an air inlet hole and an air outlet hole are respectively connected to a ventilation cavity, filter cotton is installed in the ventilation cavity, a pressing plate is located in a groove and can move up and down in the groove, the lower surface of the pressing plate is inserted into a sliding groove provided at the bottom of the groove through a shaft, a first spring is wound on the shaft, the first gear and the teeth provided on the side surface of the first gear are engaged to drive the first gear to rotate when the rack moves downward, the wind wheel is connected to a second gear through a shaft, and the second gear and the first gear are connected and driven by a wheel set installed on the right base plate. The pressing plate of the application is pressed to make the first gear rotate, the rotating wind wheel inhales indoor air from the air inlet hole, the air passes through the filter cotton to purify the air, and then the purified air is discharged into the room from the air outlet hole, so that the air is circulated and purified.

The invention belongs to the technical field of intelligent medical treatment, and discloses a dynamic risk assessment method and system for light-chain amyloidosis. A traditional staging system does not consider age factors and does not consider interaction between hematology and organ remission, so that obvious defects exist in the aspect of prognosis personalized risk prediction. According to the method, a 6-month risk scoring model and a 12-month risk scoring model are created for the first time, the age, hematological remission and heart and kidney organ remission depth of a patient are subjected to weighted integration through a multivariable Cox proportional risk model, and risk scores are generated and divided into corresponding risk grades. According to the method, the independent contribution and the interactive influence of each factor on the death risk are quantified, the method is closer to the complicated biological nature of the disease, continuous monitoring, dynamic evaluation and accurate prediction of prognosis are realized, the clinical use threshold is greatly reduced, the treatment decision can be directly linked, and an objective basis is provided for the treatment decision.

A system for remote assessment of clinical response and dynamic optimization of the chemotherapy regimen in oncology, consisting of: a device for clinical assessment of patient response, designed as a physical machine structure with a housing for use on the body or at the bedside; a housing-mounted physiological sensor unit configured to record continuous or periodic measurements of heart rate, heart rate variability, respiratory rate, peripheral oxygen saturation, body temperature, physical activity and sleep-related parameters of an oncology patient during chemotherapy; a biochemical sensor unit integrated into the housing, configured to detect biochemical indicators related to response to chemotherapy and toxicity, including inflammatory markers, metabolic indicators, hematological trends or drug-related metabolites; a patient interaction unit configured to receive symptom data reported by the patient, corresponding to treatment tolerability and functional status; an embedded processing unit that is operationally connected to the physiological sensor unit, the biochemical sensor unit, and the patient interaction unit, and is configured to perform signal conditioning, temporal alignment, data integrity verification, and encryption of the acquired patient data; a communication unit that is operationally connected to the embedded processing unit and configured to transmit the processed patient data to a remote processing infrastructure using secure communication protocols; a remote processing system comprising at least one processing unit and a storage unit for storing executable instructions, wherein the processing unit is configured to aggregate longitudinal patient data across chemotherapy cycles, analyze correlations between recorded physiological data, biochemical indicators, patient-reported outcomes, and parameters of chemotherapy administration, and calculate a clinical assessment of response; and A system for interacting with physicians, configured to display the results of the clinical response assessment and generate recommendations for optimizing the chemotherapy regimen, which are subject to review and approval by the physician.

The invention relates to the technical field of medical protection equipment, in particular to an accurate chemotherapeutic drug infusion protection device for the blood oncology department. Comprising a first structure and a second structure, the first structure is used for achieving a protection effect during operation, and the second structure is arranged below the first structure and achieves an air purification effect. Comprising a first box body, the first box body is made of transparent glass, and the glass has high permeability, so that medical staff can conveniently observe the internal operation condition. An observation face is arranged at the top end of the first box body, the observation face and the transparent glass are integrally formed, the observation face is obliquely arranged, and the downwards-inclined end of the observation face is close to the first operation groove, so that the observation angle is further optimized, and accurate operation of medical staff is facilitated. Compared with the prior art, the novel chemotherapeutic device has the advantages that the first structure is arranged, the first box body, the rubber gloves and the isolation cover are utilized to form a closed operation space, harm to medical staff and patients caused by leakage of chemotherapeutic drugs is effectively avoided, and the medical rubber gloves guarantee operation flexibility and the protection effect.

The present invention relates to methods and kits for assessing the absorbed dose of ionizing radiation and the severity of tissue damage from radiation in a patient. It provides the ability to detect erroneously overexposed individuals, select individuals, optimize the schedule of countermeasure doses used for treatment, and monitor the effectiveness of tools for a particular individual.SOLUTION: A multiplex assay kit for use in assessing absorbed doses of ionizing radiation or radiation-induced tissue injury in a patient sample, said kit configured to measure the level of a plurality of biomarkers in said sample, wherein said plurality of biomarkers comprises: (a) DNA damage biomarkers; (b) inflammatory response biomarkers; (c) tissue damage biomarkers; (d) tissue damage repair biomarkers; (e) hematology surrogate markers; and (f) combinations thereof.SELECTED DRAWING: None

This invention relates to the field of biomedical technology, and more particularly to the application of XPO1 inhibitors in the preparation of drugs for the topical treatment of pruritus. Experimental studies have shown that XPO1 inhibitors have significant therapeutic effects on chronic and complex pruritus models, and may be applicable to pruritus caused by various etiologies, possessing broad-spectrum therapeutic potential. By administering the drug topically, it primarily acts on the local skin, greatly avoiding the serious systemic side effects (such as hematological toxicity and gastrointestinal reactions) associated with oral XPO1 inhibitors. Simultaneously, it also avoids the local side effects such as skin atrophy caused by long-term use of potent hormones. This invention provides a novel drug option for the treatment of intractable pruritus and related inflammatory skin diseases.

A modular, point-of-care diagnostic system for analyzing blood is provided comprising a blood sample preparation module and one or more analytical modules including a hematology analysis module and a chemistry analysis module disposed within a housing. The system comprises common biological fluid handling hardware disposed in the housing and configured to convey blood samples or portions thereof between the blood sample preparation module, the one or more analytical modules, and a consumable reagent cartridge comprising one or more reagents for a first set of tests or controls. The system comprises common wash fluid handling hardware for preparing the common fluid handling hardware and fluid-contacting surfaces of the one or more analytical modules for interaction with a second consumable reagent cartridge containing reagents for a second set of tests or controls by the one or more analytical modules.